Alumis Inc. (ALMS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Alumis reported revenue of $24.1M. Net income was -$243.3M (a -1011.7% net margin), or -$2.86 per diluted share. Operating margin was -1886.9%. Operating activities generated -$369.5M of cash, leaving -$370.2M of free cash flow. At fiscal year end, Alumis held $411.9M in total assets against $110.6M in total liabilities, including $89.7M of cash and equivalents.
Open the full interactive Alumis financials → Quarterly statements, key ratios, valuation history and price charts.
Alumis Key Stats
| Share Price | $6.56 |
|---|---|
| Market Cap | $837.6M |
| 52-Week Range | $4.49 – $30.30 |
| Shares Outstanding | 127.7 million (basic, 2026 Q2) |
Alumis Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $24.1M |
| Operating Income | -$300.8M | -$453.8M |
| Pre-Tax Income | -$294.2M | -$251.9M |
| Income Tax | $0 | -$8.6M |
| Net Income | -$294.2M | -$243.3M |
| Diluted EPS | -$10.38 | -$2.86 |
Alumis Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $2.1M | $1.9M | $1.7M | $1.7M |
| Net Income | -$110.8M | -$92.9M | -$93.1M | -$142.2M |
| Diluted EPS | -$1.06 | -$1.09 | -$0.74 | -$1.11 |
Alumis Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $169.5M | $89.7M |
| Current Assets | $306.2M | $318.2M |
| Total Assets | $341.0M | $411.9M |
| Current Liabilities | $50.9M | $73.3M |
| Total Liabilities | $80.9M | $110.6M |
| Shareholders' Equity | $260.1M | $301.3M |
Alumis Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$255.1M | -$369.5M |
| Cash From Investing | -$113.8M | $287.9M |
| Cash From Financing | $492.4M | $2.1M |
| Free Cash Flow | -$256.8M | -$370.2M |
Figures from Alumis' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Alumis financials page for every line item.
Alumis Company Profile
| Ticker | ALMS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001847367 |
Frequently Asked Questions
What was Alumis' revenue in fiscal 2025?
Alumis (ALMS) reported revenue of $24.1M for fiscal 2025.
What was Alumis' net income in fiscal 2025?
Alumis reported net income of -$243.3M for fiscal 2025.
What was Alumis' earnings per share (EPS) in fiscal 2025?
Alumis' diluted EPS was -$2.86 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Alumis generate in fiscal 2025?
Alumis generated -$370.2M of free cash flow in fiscal 2025.
What was Alumis' revenue last quarter?
In its most recent reported quarter (2026 Q2), Alumis reported revenue of $1.7M.
How many shares of Alumis are outstanding?
Alumis reported a weighted average of 127.7 million basic shares outstanding in 2026 Q2.
What is Alumis' market cap?
Based on its latest closing price, Alumis (ALMS) has a market capitalization of about $837.6M.
When does Alumis' fiscal year end?
Alumis' fiscal year end, as registered with the SEC, is December 31.
Where is Alumis headquartered?
Alumis lists its business address in South San Francisco, California in its SEC filings.